Abstract
The mechanisms underlying the anti-inflammatory properties of salicylate are not well understood. In particular, while salicylate inhibits prostaglandin production in vivo it only weakly inhibits cyclooxygenase (COX)-1 or -2 activity in vitro. Thus, it has often been suggested that in vivo salicylate may inhibit the expression rather than the activity of COX, particularly COX-2. Using a model of acute COX-2 expression in the rat, we show that salicylate inhibits COX-2 activity in vivo without affecting COX-2 expression. In anesthetized rats LPS (6 mg kg−1, i.p.) increased the expression of COX-2 as evidenced by increased circulating levels of 6-keto-prostaglandin F1α (6-keto-PGF1α, a stable breakdown product of PGI2), greatly exaggerated formation of 6-keto-PGF1α following arachidonic acid (AA) challenge (3 mg kg−1, i.v.), and increased expression of COX-2, but not COX-1, protein. Diclofenac (3 mg kg−1, i.p.) or the COX-2 selective agent diisopropyl fluorophosphate (10 mg kg−1, i.p.) decreased the LPS-induced increase in circulating 6-keto-PGF1α and the exaggerated 6-keto-PGF1α production following AA challenge. Sodium salicylate (20 or 120 mg kg−1, i.p.) (administered either 1 h prior, or once per day for 3 days prior, to LPS injection) reduced only the LPS-induced increase in circulating 6-keto-PGF1α, but not the exaggerated 6-keto-PGF1α production following AA challenge or the expression of COX-2. Thus, salicylate inhibits LPS-induced COX-2 activity in a manner that is overcome by provision of excess substrate and independent of effects on COX-2 expression. In conclusion, our results exclude mechanisms other than direct enzyme inhibition as responsible for the anti-COX effects of salicylate.
Footnotes
-
This work was supported by a grant from Boehringer Ingelheim Pharma KG.
-
J.A.M. is a Wellcome Career Development Fellow.
- Abbreviations:
- COX
- cyclooxygenase
- AA
- arachidonic acid
- NO
- nitric oxide
- iNOS
- inducible NO synthase
- LPS
- lipopolysaccharide
- NF-κB
- nuclear factor κB
- NSAIDs
- nonsteroidal anti-inflammatory drugs
- PG
- prostaglandin, ANOVA, analysis of variance
- DFP
- diisopropyl fluorophosphate
- Received May 25, 2001.
- Accepted August 15, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|